Effects of inhaled corticosteroids in monotherapy or combined with long-acting β2-agonists on mortality among patients with chronic obstructive pulmonary disease

Annals of Pharmacotherapy

Volumn 44, Issue 4, 2010, Pages 613-622

  Cyr, Marie Christyne ^a   Beauchesne, Marie France ^a,b   Lemiére, Catherine ^a,b   Aaron, Shawn D ^c,d,e   Blais, Lucie ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Administrative database; Chronic obstructive pulmonary disease; Inhaled corticosteroids; Long acting ( 2 agonists; Mortality

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; ORCIPRENALINE; PIRBUTEROL; SALBUTAMOL; SALMETEROL; TERBUTALINE;

ADULT; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DEATH; DRUG EFFECT; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL SERVICE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUEBEC; RECEPTORS, ADRENERGIC, BETA-2; SAMPLE SIZE; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 77950619455     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M243     Document Type: Article

References (40)

1. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 2007;14(suppl B):5B-32B. (Pubitemid 350090390)
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276
3. World Health Organisation 2008. The Global Burden of Disease 2004 Update. World Health Organisation, 2008:1-160. http://www.who.int/healthinfo/global- burden-disease/GBD-report-2004update-full. pdf (accessed 2009 Nov 19).
4. The Center for Chronic Disease Prevention and Control, Health Canada, Canadian Institute for Health Information. Editorial Board Respiratory Disease In Canada. Ottawa: Health Canada, 2003.
5. Lenfant C, Khaltaev N. Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (update 2005). 2005:72. www.goldcopd.com/ Guidelineitem.asp?11=2&12=1&intId=1620 (accessed 2009 Nov 19)
6. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909 (Pubitemid 32064783)
7. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303 (Pubitemid 30245717)
8. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351:773-780 (Pubitemid 28112338)
9. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-1953 (Pubitemid 29288270)
10. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456 (Pubitemid 36173708)
11. Celli B, Calverley P, Anderson J, Ferguson G, Jenkins C, Jones P, et al. The TORCH (TOwards aRevolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years (abstract). Eur Respir J 2006;28:34.
12. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81. (Pubitemid 36150304)
13. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919 (Pubitemid 37540641)
14. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-149 (Pubitemid 46115085)
15. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-997 (Pubitemid 41705466)
16. Ernst P, Suissa S. Inhaled corticosteroids and mortality in COPD. Thorax 2006;61:735.
17. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789 (Pubitemid 46294610)
18. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Chest 2006;130:640-646 (Pubitemid 44570304)
19. Gudmundsson G, Gislason T, Lindberg E, et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006;7:109. (Pubitemid 44355989)
20. Kiri VA, Pride NB, Soriano LB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease-results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005;172:460-464 (Pubitemid 41117392)
21. Mapel DW, Hurley JS, Roblin D, et al. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med 2006; 100:595-609. (Pubitemid 43285746)
22. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003;2:67-74. (Pubitemid 37062718)
23. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-584 (Pubitemid 32801660)
24. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20:819-825 (Pubitemid 35175115)
25. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003;168:1488-1494 (Pubitemid 38037334)
26. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53. (Pubitemid 37046632)
27. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004;23:391-395 (Pubitemid 38344374)
28. Régie de l'assurance maladie du Québec. Statistiques annuelles. Québec: Régie de l'assurance maladie du Québec, Health Ministry, Government of Québec, 1999.
29. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
30. Pilote L, Lavoie F, Ho V, Eisenberg MJ. Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995. CMAJ 2000;163:31-36 (Pubitemid 30490317)
31. Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005;330:230. (Pubitemid 40188074)
32. McKnight J, Scott A, Menzies D, Bourbeau J, Blais L, Lemiere C. A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J Clin Epidemiol 2005;58:206-208 (Pubitemid 40174931)
33. Etminan M. Pharmacoepidemiology II: the nested case-control study - a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004;24:1105-1109 (Pubitemid 39128834)
34. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984;40:63-75.
35. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
36. Bice TW, Boxerman SB. A quantitative measure of continuity of care. Med Care 1977;15:347-349
37. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007;16:241-249 (Pubitemid 46431687)
38. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven, 1998.
39. Niewoehner DE. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"? COPD 2009;6:1-3.
40. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-2312 (Pubitemid 37430563)